Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS–International Prognostic Index (CNS-IPI) risk model may improve identification of patients at high risk for developing secondary CNS disease. CNS relapse was analyzed in 1418 DLBCL patients treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy in the phase 3 GOYA study. Cell of origin (COO) was assessed...
Thu Feb 28, 2019 19:00
DUBLIN--(BUSINESS WIRE)--The "Ankylosing Spondylitis (Bekhterev's Disease) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Global Ankylosing Spondylitis (Bekhterev's Disease) Clinical Trials Review, H2, 2018" provides an overview of Ankylosing Spondylitis (Bekhterev's Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Ankylosing Spondylitis (Bekhterev's Disease). Report includes
Thu Feb 28, 2019 18:07
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. to Present at the World Immunotherapy Congress USA 2019
Thu Feb 28, 2019 18:05
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced seven presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia. Details of Arcus’s Presentations are as follows: ORAL PRESENTATION: AB680 (small-molecule CD73 inhibitor) Title: Development of potent and selective CD73 inhibitors
Thu Feb 28, 2019 15:30
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the acceptance for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2019 of an abstract describing results of preclinical studies of tesetaxel, Odonate’s investigational, orally administered taxane. These preclinical results indicate th
Thu Feb 28, 2019 15:30
GAITHERSBURG, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that it will present novel preclinical data on SNS-723, a first-in-class CAR-T cell therapy and additional Phase 1 data on the long-term effects of SNS-301, a first-in-class cancer immunotherapy, both targeting a novel tumor specific embryonic antigen, human aspartate β-hydroxylase (ASPH), at the American Association for Can
Thu Feb 28, 2019 15:01
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the new serotypes included in its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes covered in the vaccine in adults aged 18 years and older. Pfizer’s 20vPnC candidate includes the 13 serotypes contained in Prevnar 13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) plus 7 additional
Thu Feb 28, 2019 15:00
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided an overview of the Company’s recent developments. “Our clinical and corporate execution in 2018 places UroGen in a position of strength as we prepare to potentially deliver UGN-101 as the first approved therapy for patients w
Thu Feb 28, 2019 15:00
WILMINGTON, Del.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank"gt;$INCYlt;/agt; lt;a href="https://twitter.com/hashtag/AACR19?src=hash" target="_blank"gt;#AACR19lt;/agt;--Data from Incyte’s Cancer Research Portfolio to be Featured in Seven Abstracts at the AACR Annual Meeting 2019
Thu Feb 28, 2019 15:00
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals Recognizes Rare Disease Day® 2019
Thu Feb 28, 2019 15:00
LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;--Concert reported 2018 financial results and provided an update on its product pipeline and corporate activities.
Thu Feb 28, 2019 14:00
SAN FRANCISCO--(BUSINESS WIRE)--Maze Therapeutics Launches with $191 Million to Focus on Translating Genetic Insights into New Medicines
Thu Feb 28, 2019 14:00
DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent of teprotumumab patients compared to 9.5 percent of placebo patients achieved the primary endpoint of a 2 mm
Thu Feb 28, 2019 14:00
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq:EGRX) today announced its financial results for the three months and full year ended December 31, 2018. Highlights of, and subsequent to, the fourth quarter of 2018 include: Business and Recent Highlights: Commenced enrollment in a study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium) in collaboration with the United States Army Medical Research Institute of Chemical De
Thu Feb 28, 2019 13:50
Publication date: Available online 27 February 2019Source: Contemporary Clinical TrialsAuthor(s): Xiaojun Shi, Daniel J. Buysse, Lee M. Ritterband, Susan M. Sereika, Patrick J. Strollo, Sally E. Wenzel, Faith S. LuysterAbstractBackgroundChronic insomnia is associated with poor asthma control. Cognitive-behavioral treatment for insomnia (CBT-I) is an efficacious and durable treatment for comorbid insomnia in medical and psychiatric disorders. However, the efficacy and potential accompanying mechanisms...
Thu Feb 28, 2019 13:46
ST. HELIER, Jersey--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24NVCR&src=ctag" target="_blank"gt;$NVCRlt;/agt;--Novocure today reported financial results for the quarter and year ended December 31, 2018.
Thu Feb 28, 2019 13:00
スイス・ルガーノ & スペイン・バルセロナ--(BUSINESS WIRE)--（ビジネスワイヤ） -- GT Gain Therapeutics SA（代謝異常と中枢神経系疾患の先天異常に関与するリソソーム酵素を標的とする新規治療薬の創薬と開発に取り組むバイオテクノロジー企業）は本日、マイケル・J・フォックス・パーキンソン病リサーチ財団（MJFF）とGBA変異パーキンソン病シルバースタイン財団から、パーキンソン病向けの当社専有の非競合的分子シャペロンを発展させるべく、資金援助を受けたと発表しました。この助成はスペイン・バルセロナにあるバルデブロン研究所のマルタ・マルチネス・ビンセント医師と共に授与されました。 MJFFとシルバースタイン財団による助成は、グルコセレブロシダーゼ（GBA）遺伝子に変異があるパーキンソン病に対するGain Therapeuticsの新規治療手法が評価されたことを示しています。Gainの技術プラットフォームは、リソソーム酵素の機能、すなわちたたみ込みと細胞内移動が影響を受けている疾患を対象に、脳透過性のアロステリックな非阻害的薬理学的シャペロンを突き止めて
Thu Feb 28, 2019 12:59
COPENHAGUE, Dinamarca--(BUSINESS WIRE)--Las compañías farmacéuticas Janssen de Johnson & Johnson han aunciado hoy la presentación de 18 resúmenes patrocinados por la empresa en el 14º congreso de la European Crohn’s and Colitis Organisation, la asociación europea para la colitis y la enfermedad de Crohn, que tendrá lugar en Copenhague, Dinamarca, del 6 al 9 de marzo. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayu
Thu Feb 28, 2019 12:30
The approval allows Nuformix to initiate the first dosing of NXP001 in an open-label study to compare the bioavailability of NXP001 to Merck’s EMEND in healthy subjects. Nuformix The post Nuformix announces UK MHRA approval to start NXP001 human pharmacokinetics studies appeared first on Pharmaceutical Business review.
Thu Feb 28, 2019 14:10
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου